Methods of treating psoriasis using IL-17 receptor A antibodies
View Patent ↗The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
1. A method of treating psoriatic arthritis, comprising administering to a patient having psoriatic arthritis a composition comprising an human monoclonal antibody selected from the group consisting of:
a. an isolated antibody, comprising a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14; and
b. an isolated antibody, comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147 and a heavy chain CDR3 comprising SEQ ID NO:148,
wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
2. The method of claim 1 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
3. The method of claim 1 , wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.
4. The method of claim 1 , wherein said antibody is selected from the group consisting of:
a.
an IgG1 antibody;
b. an IgG2 antibody;
c. an IgG3 antibody; and
d. an IgG4 antibody.
5. The method of claim 1 , wherein said antibody is selected from the group consisting of:
a.
an IgG1 antibody; and
b. an IgG2 antibody.
6. The method of claim 1 , wherein said composition is a pharmaceutical composition.
7. The method of claim 6 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
8. The method of claim 1 , wherein said antibody is a human IgG2 monoclonal antibody.
9. The method of claim 1 , wherein said composition is a pharmaceutical composition.
10. The method of claim 9 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
11. A method of treating psoriatic arthritis, comprising administering to a patient having psoriatic arthritis a composition comprising an isolated human monoclonal antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147 and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
12. The method of claim 11 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
13. The method of claim 12 , wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.
14. The method of claim 11 , wherein said composition is a pharmaceutical composition.
15. The method of claim 14 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
16. The method of claim 11 , wherein said antibody is selected from the group consisting of:
a.
an IgG1 antibody;
b. an IgG2 antibody;
c. an IgG3 antibody; and
d. an IgG4 antibody.
17. The method of claim 11 , wherein said antibody is selected from the group consisting of:
a.
an IgG1 antibody; and
b. an IgG2 antibody.
18. The method of claim 11 , wherein said antibody is a human IgG2 monoclonal antibody.
19. The method of claim 18 , wherein said composition is a pharmaceutical composition.
20. The method of claim 19 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
21. A method of treating psoriatic arthritis, comprising administering to a patient having psoriatic arthritis a composition comprising an isolated antibody comprising a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
22. The method of claim 21 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
23. The method of claim 22 , wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.
24. The method of claim 21 , wherein said composition is a pharmaceutical composition.
25. The method of claim 24 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
26. The method of claim 21 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a diabody;
h. a triabody;
i. a tetrabody;
j. a Fab fragment;
k. a F(ab')2 fragment;
l. an IgD antibody;
m. an IgE antibody;
n. an IgM antibody;
o. an IgG1 antibody;
p. an IgG2 antibody;
q. an IgG3 antibody; and
r. an IgG4 antibody.
27. The method of claim 21 wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a humanized antibody;
c. a chimeric antibody;
d. a monoclonal antibody;
e. an antigen-binding antibody fragment;
f. a single chain antibody;
g. a Fab fragment;
h. a F(ab')2 fragment;
i. an IgG1 antibody; and
j. an IgG2 antibody.
28. The method of claim 21 , wherein said antibody is a human antibody.
29. The method of claim 21 , wherein said antibody is a monoclonal antibody.
30. The method of claim 21 , wherein said antibody is a human monoclonal antibody.
31. The method of claim 21 , wherein said antibody is a human IgG2 monoclonal antibody.
32. The method of claim 31 , wherein said composition is a pharmaceutical composition.
33. The method of claim 32 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
34. A method of treating psoriatic arthritis, comprising administering to a patient having psoriatic arthritis a composition comprising an isolated antibody comprising a light chain sequence comprising amino acids 21-234 of SEQ ID NO:429 and a heavy chain sequence comprising SEQ ID NO:427, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17 A to said IL-17 receptor A.
35. The method of claim 34 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
36. The method of claim 35 , wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.
37. The method of claim 24 , wherein said composition is a pharmaceutical composition.
38. The method of claim 34 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a monoclonal antibody;
c. a single chain antibody;
d. a diabody;
e. a triabody;
f. a tetrabody; and
g. an IgG2 antibody.
39. The method of claim 34 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a monoclonal antibody;
c. a single chain antibody; and
d. an IgG2 antibody.
40. The method of claim 34 , wherein said antibody is a human antibody.
41. The method of claim 34 , wherein said antibody is a monoclonal antibody.
42. The method of claim 34 , wherein said antibody is a human monoclonal antibody.
43. The method of claim 39 , wherein said antibody is a human IgG2 monoclonal antibody.
44. The method of claim 43 , wherein said composition is a pharmaceutical composition.
45. The method of claim 44 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
46. A method of treating psoriatic arthritis, comprising administering to a patient having psoriatic arthritis a composition comprising an isolated human monoclonal antibody comprising a light chain sequence encoded by a polynucleotide comprising nucleotides 84-741 of SEQ ID NO:428 and a heavy chain sequence encoded by a polynucleotide comprising SEQ ID NO:426, wherein said antibody is produced from a Chinese Hamster Ovary Cell (CHO cell), and wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.
47. The method of claim 46 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition.
48. The method of claim 47 , wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.
49. The method of claim 46 , wherein said composition is a pharmaceutical composition.
50. The method of claim 49 , wherein said composition pharmaceutical composition further comprises a pharmaceutically acceptable diluent.
51. The method of claim 46 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a monoclonal antibody;
c. a single chain antibody;
d. a diabody;
e. a triabody;
f. a tetrabody; and
g. an IgG2 antibody.
52. The method of claim 46 , wherein said antibody is selected from the group consisting of:
a. a human antibody;
b. a monoclonal antibody;
c. a single chain antibody; and
d. an IgG2 antibody.
53. The method of claim 46 , wherein said antibody is a human antibody.
54. The method of claim 46 , wherein said antibody is a monoclonal antibody.
55. The method of claim 46 , wherein said antibody is a human monoclonal antibody.
56. The method of claim 46 , wherein said antibody is a human IgG2 monoclonal antibody.
57. The method of claim 56 , wherein said antibody is glycosylated.
58. The method of claim 57 , wherein said composition is a pharmaceutical composition.
59. The method of claim 58 , wherein said composition pharmaceutical composition further comprises a pharmaceutically acceptable diluent.